Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Consensus Recommendations – Management of Patients with Malignant Lymphoma

ESMO Consensus Conference on Malignant Lymphoma: Management of ‘ultra-high-risk’ Patients

Published in 2018 – Ann Oncol (2018); 29: 1687–1700
Authors: M. Hutchings, M. Ladetto, C. Buske, P. de Nully Brown, A.J.M. Ferreri, M. Pfreundschuh, N. Schmitz, A. Sureda Balari, G. van Imhoff, J. Walewski & the ESMO Lymphoma Consensus Conference Panel Members

In order to complement the already available European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with malignant lymphomas, ESMO organised a consensus conference on mature B-cell lymphomas and chronic lymphocytic leukaemia to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (i) the elderly patient, (ii) prognostic factors suitable for clinical use and (iii) the 'ultra-high-risk' group.

This manuscript presents recommendations on the clinical management of ‘ultra-high-risk’ patients with malignant lymphoma and was compiled by a multidisciplinary panel of 25 experts. It provides clear guidance on the management of the following high-risk situations: DLBCL with CNS relapse, primary refractory HL and PBL. Recommendations provided are accompanied by relevant supporting evidence.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings